

Genetic Detection and Identification of Some Virulence Factors Genes Among *Pseudomonas aeruginosa* Samples in Kirkuk province-Iraq

Ibraheem Salih Aljebory

College of Education/Alhawija, Kirkuk University, Iraq.

Received: 09th July, 19; Revised: 05th August, 19, Accepted: 09th September, 19; Available Online: 23th September, 2019

ABSTRACT

The study aim was to identify the prevalence of some virulence factors genes of *Pseudomonas aeruginosa* isolates which carried out at Kirkuk hospitals, in Kirkuk, Iraq. Totally 150 swaps were collected and cultured (110 patients suffered from burns, and 40 patients suffered from wounds) from different ages and both gender for identification of *P. aeruginosa*, the bacterial swaps were detect by biochemical tests, API 20 E and Vitak 2 system. 51 (34%) isolates of *P. aeruginosa* of total samples were identified, distributed as 39 isolates (35%) from burns and 12 isolates (3%) from wounds. Depending on groups of ages and gender, the study indicated that the rate of *P. aeruginosa* in the male was (53%), and in female patients was (47%) and the maximum rate (28%) was between 24-29 years comparison with the elderly. Bacterial chromosomal DNA was extracted from *P. aeruginosa* by QIAamp DNA mini kit. The average DNA concentration of 51 DNA samples were 85 ng/μl and the average purity were 1.9. Polymerase chain reaction (PCR) has been used to identified the virulence factor genes (*tox A* and *opr L*). The result indicated that 50 (98%) samples were positive for *opr L* and 51 (100%) for *tox A* genes.

Keywords: *Opr L*, *P. aeruginosa*, *Tox A* genes and Virulence genes.

International Journal of Pharmaceutical Quality Assurance (2019); DOI: 10.25258/ijpqa.10.3.8

How to cite this article: Aljebory, I.S. (2019). Genetic Detection and Identification of Some Virulence Factors Genes Among *Pseudomonas aeruginosa* Samples in Kirkuk province-Iraq. International Journal of Pharmaceutical Quality Assurance 10(3): 147-150.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

P. aeruginosa is an opportunistic pathogen which causes a large variety of individual infections and opportunistic pathogen. It is a frequent hospital-acquired pathogen and accountable for urinary tract infections, bacteremia, dermatitis, soft tissue infections respiratory infections, bone and joint infections, gastrointestinal infections, and systemic infections diversity, mainly in patients with bed ulcers, severe burns, and AIDS or cancer's patients who are immunosuppressed¹⁻³ and with limited therapeutic options because of its antibiotic resistance.⁴ Resistance to antibiotic constitutes is one of the most serious threats to the worldwide public health and impacts all aspects of therapeutics, animal husbandry and agriculture; it is natural, ancient, and hard wired in the microbial pan-genome.⁵ In hospitals, *P. aeruginosa* infections mainly have an effect on the patients in the units of intensive care and those having catheterization, burn, and/or chronic illnesses.⁶ The mainly essential virulence factors of *P. aeruginosa* involved outer membrane-associated protein L and I, exotoxin A (ETA) and quorum-sensing determinant system.⁷ Exotoxin A be the main hazardous virulence factor formed by *P. aeruginosa*.⁸ The external membrane proteins (*OprI* and *OprL*) of *P. aeruginosa* play an essential role in the relations of the bacterium with the

surroundings, as well as *P. aeruginosa* inherent resistance to the antibiotics. Besides, the specific outer membrane proteins have been concerned in the efflux transport systems that have an effect on cell permeability.⁹ Because of these proteins are present only in this organism, they could be a dependable factor for rapid detection of *P. aeruginosa* in clinical samples.¹⁰ The virulence of *P. aeruginosa*, fundamentally depends on two kinds of virulence determinants: virulence factors included in acute infection, they seem often secreted and membrane-bound factors. There are a great number of virulence factors for *P. aeruginosa* such as elastase, sialidase, exoenzyme S, and exotoxin A¹¹ as well as, there are a number of others extracellular products. Exotoxin A encoded by the *tox A* gene which has the capability of protein biosynthesis inhibition just like diphtheria toxin.^{12,13}

MATERIALS AND METHOD

Collection of samples:

One hundred and fifty samples were collected (40 wounds patients, 110 burns patients) from Kirkuk hospitalized burns and wounds care units, in Kirkuk, Iraq. During June to August 2018. Samples were cultured on Cetrimide agar, Blood agar, King A and king B medium, and MacConkey agar. The

biochemical tests were performed for confirmed the detection *P. aeruginosa* isolates by oxidase, catalase, motility, IMVIC tests.¹⁴ The biochemical tests result of final recognition of *P.aeruginosa* was reliant on Api 20 E, and Vitak 2 systems.

DNA extraction and PCR Method

DNA Extraction

DNAs were extracted by QIAamp DNA mini kit (Qiagen, Germany) depending on the manufacturer's protocols and checked via Electrophoresis instrument in a 1% agarose gel which stained by ethidium bromide, then take a look via ultra violet transilluminator (UVT).

Nanodrop

Chromosomal DNA has measured by the device of nanodrop at 260/280nm, and preserved at (-20°C) till further uses.

Polymerase chain reaction analysis

The PCR technique has done for factors of virulence genes which were exotoxin A (*toxA*) and outer membrane protein (*oprL*) genes in *P. aeruginosa* by specific primers. PCR amplification was done by thermal cycler instrument (BioRad, USA) with using two specific primers for *oprL* and *toxA* genes. Table 1.

The PCR was done in 50 µL volume reaction mixtures which contain 1µL of primers, 10 µL of DNA template and 25 µl of master mix. The suitable temperature of annealing was performed at 55°C for, *oprL* and *toxA*.¹⁵

Product analysis

Products of PCR has been analysis via gel electrophoresis instrument in 1.5% agarose gel stained with ethidium bromide then visualized and documented under UVT.

Table 1: primers and their sequence and amplicon.

Amplified gene (Primers)	Sequence (5'@3')	Amplicon
oprL	F, 5'-ATG GAA ATG CTG AAA TTC GGC-3'	500 bp
	R, 5'-CTT CTT CAG CTC GAC GCG ACG-3'	
toxA	F, 5' GGT AAC CAG CTC AGC CAC AT 3'	352bp
	R, 5' TGA TGT CCA GGT CAT GCT TC 3'	

Table 2: Percentage and number of *P. aeruginosa*.

Samples type	Total samples	Positive samples	Negative samples	Percentage %
Burns	110	39	71	35%
Wounds	40	12	28	3%

Table 3: Percentage and distribution *P. aeruginosa* depending on gender.

	Male	Female
Positive isolates	27	24
Percentage	53%	47%

Table 4: The wound and Burn frequency of Patients (%) Involved in *P. aeruginosa* Depending on Different Groups of Age.

Age group	1-5	6-11	12-17	18-23	24-29	30-35	36-41	42-47	48-53	54-59
Rate %	10	12	16	20	28	4.3	5	3.7	0.5	0.5

Study Results

In this study, from 150 samples 51 (34%) isolates of *P.aeruginosa*, 39 (35%) from burns, and 12(3%) from wounds as in Table 2.

For 53% (n = 27) and 47% (n = 24) of *P.aeruginosa* samples were isolated from male infected and female infected, respectively as in Table 3.

Also, the ages of patients are ranged between 1-59 years and the greater part between 24-29 years as in below Table 4.

The study results showed that the DNA samples concentration of the fifty-one *Pseudomonas aeruginosa* isolates were 85 ng/uL, and the average purity was 1.9, Figure 1.

Study results showed the distribution of *P. aeruginosa* virulence factors genes were 50 (98%) isolates were positive for *oprL* and 1 (2%) were PCR negative while the *toxA* gene were detected in all of the 51 (100%) *P aeruginosa* isolates as in Table 5.

For identification of virulence factors genes of *P. aeruginosa* (*toxA* and *oprL*), polymerase chain reaction was done and obtained. PCR results of *toxA* gene (352bp) and *oprL* gene (500bp) expression are demonstrated in Figures 2 and 3, respectively.

DISCUSSION

P.aeruginosa is the most important cause of nosocomial infections. Infections caused by it are frequently severe and life-threatening and difficult to treat as the organism is inherently resistant to several drug classes and has the ability to gain resistance to all active antibacterial antibiotics. Over the years, *P. aeruginosa* contributes substantially to morbidity and mortality related to surgical site infection global, the third most frequently reported nosocomial infection.¹⁶ Also, Patients of burn are further liable to have infections in compare




Figure 1: A run of agarose gel electrophoresis of the DNA samples.

Table 5: Number and percentage of genes of positive isolates.

Type of genes	Positive isolates	Percentage
oprL	50	98 %
toxA	51	100%




Figure 2: PCR product at Agarose Gel electrophoresis for the identification of *oprL* gene (500bp) by using 1% agarose, stained with ethidium bromide, M: 100bp DNA Ladder, Lanes 1 negative control. Lanes (2-18): Positive for *oprL* gene (500bp).

with other patients due to their damaged of barriers skin and suppressed immune system, in order to extended hospital stay diagnostic procedures and invasive therapeutic.¹⁷ Findings come with same results more or less with others in Karbala city, Iraq,¹⁸ which showed that the highest percentage of bacterial isolate in burn patients had the bacteria *P. aeruginosa*, (45%) and (49%) with Alhamdy.¹⁹ Most of burn patients die because of infections through their hospital courses. The infection rate in burn cases is too high in developing countries.^{20,21} This may be as a result of the prevalence of poor socioeconomic groups of patients in whom low-level hygienic conditions prevail.²² Also varying in common rate among several studies perhaps imputed to varieties in geographical position and hygienic practices. Depending on gender groups and age, the results of study indicates that *P. aeruginosa* rate is 28% for young patients (ages 24 to 29 years) and in the male (53%), comparison with the elderly, agree with Al-Zaidi, et²³ shows males in this group of age are more effective which include different clinical hygiene practices, for hospital environment.. This study is compared with the results of Okon *et al.* in Nigeria, who registered that the male patients showed a record of 52.8% and the highest frequency of this bacterium was (20.7%) that establish for an age of 29 years old and below.²⁴ In contrast, these results differ with results in Karbala city, Iraq¹⁸, results of Ekrem and R okan in Al- Sulaimania city, Iraq²⁵ and Shewatatek et al.²⁶ in Ethiopia, study results indicated a higher incidence of the bacterium in female and elderly patients. Many of the virulence factors formed by *P. aeruginosa* are ordered with diverse systems.²⁷ Farther last studies show *P. aeruginosa* is mainly common pathogen which produced several virulence factors genes such as (*ToxA*, *exoA*, *oprL*, and *oprI*) genes.²⁸ The results of PCR illustrated that, 50 of 51 *P. aeruginosa* isolates were positive for the *oprL* gene with amplified size (500 bp) in a percentage (98%), similar to this study, the total isolates of *P. aeruginosa* (100%) were positive for both *oprL* and *oprI* genes.²⁹ *P. aeruginosa* has a diversity of virulence factors that may take part to its pathogenicity. Our results showed that *toxA* gene (352bp) were detected in all 51(100%) tested strains of *P. aeruginosa*, The distributions of virulence factor genes are varieties in the populations that empower the probability of some *P. aeruginosa* strains are best adapted to the specific conditions which found in specific infectious locations³⁰ that may returned to the different environmental and geographical




Figure 3: PCR product at agarose Gel electrophoresis for the identification of *toxA* gene (352bp) by using 1% agarose, stained with ethidium bromide, M: 100bp DNA Ladder, Lanes 1 negative control. Lanes (2-18): Positive for *toxA* gene (352bp).

sources. *P. aeruginosa* percentage and frequency of virulence factors genes depending on the numerous reasons such as sites nature, kinds and virulence of strain, immune status of patients, and extent of contamination.³¹

CONCLUSION

Conclusions of the outcome study show that a high rate of infected wounds and burns of *P. aeruginosa* may occur as a result of common apply and antibiotics mistreatment. So the results of the study may be as a recommendation to the accurate antibiotics using for treatment of patients. PCR seems that concurrent use of specific primers different virulence factors genes as (*oprL* and *toxA*) of *P. aeruginosa* provides more confident detection of *P. aeruginosa*. Also, its varieties in the virulence factor genes distributions in the isolated strains need further studies for existing out the real role of these *P. aeruginosa* genes from different sources. PCR showed that all *P. aeruginosa* strains do not necessarily have similar virulence genes.

REFERENCES

- 1 Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. *Antimicrob Agents Chemother.* 2006;50(1): 43–8.
- 2 Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with *Pseudomonas aeruginosa* bacteremia in patients with cancer: Retrospective analysis of 245 episodes. *Arch Intern Med.* 2000;160(4):501–9.
- 3 Gad GF, El-Domany RA, Zaki S, Ashour HM. Characterization of *Pseudomonas aeruginosa* isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. *J Antimicrob Chemother.* 2007;60(5):1010–7.
- 4 Empel J, Filczak K, Mrówka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of *Pseudomonas aeruginosa* Infections with PER1 Extended-Spectrum b-Lactamase in Warsaw, Poland: Further Evidence for an International Clonal Complex. *J Clin Microbiol* 2007; 45: 2829-2834.)
- 5 Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, Barton HA, Wright GD. Antibiotic resistance is prevalent in an isolated cave microbiome. 2012. *PLOS ONE* 7:e34953 DOI 10.1371/journal.pone.0034953.
- 6 Yetkin G, Oflu B, Cicek A, Kuzucu C, Durmaz R. Clinical, microbiologic, and epidemiologic characteristics of

- Pseudomonas aeruginosa* infections in a university hospital, Malatya, Turkey. *Am J Infect Control*. 2006 34: 188-192.
- 7 Gellatly S.L and Hancock R.E. *Pseudomonas aeruginosa*: new insights into pathogenesis and host defenses. *Pathogens and disease*. 2013;67(3):159-173.CrossRef
 - 8 El-Din A.B, EL-Nagdy M.A, Badr R and EL-Sabagh A.M. *Pseudomonas aeruginosa* exotoxin A: its role in burn wound infection and wound healing. *Egypt J Plast Reconstr Surg*. 2008;32:59-65.)
 - 9 Nikaido H. Prevention of drug access to bacterial targets: Permeability barriers and active efflux. *Sci*. 1994;264:382-388.
 - 10 De Vos D, Lim A, Pirnay JP, Struelens M, Vandenveld C. Direct detection and identification of *Pseudomonas aeruginosa* in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane genes, *oprI* and *oprL*. *J Clin Microbiol*. 1997;35:1295-1299.
 - 11 Green, M., Apel, A. & Stapleton, F. A longitudinal study of trends in keratitis in Australia. *Cornea* 2008. 27: 33-39.
 - 12 Hamood, A.N.; Colmer-Hamood, J.A. and Carty, N.L.. Regulation of *Pseudomonas aeruginosa* exotoxin A synthesis. In *Pseudomonas: Virulence and gene regulation*. Academic/plenum publishers, New York, 2004:389-423PP.
 - 13 VanDelden, C. and Iglewski, B.H. Cell-to-cell signaling and *Pseudomonas aeruginosa* infections. *Emerg. Infect. Dis.*, 1998; 4(4): 551- 560.
 - 14 Giraldi GL. *Pseudomonas* and related genera. *Manual of clinical microbiology* 5th ed. American Society for Microbiology, Washington D.C. 1990; 429-441.
 - 15 Khattab MA, Nour MS, ElSheshtawy NM. Genetic Identification of *Pseudomonas aeruginosa* Virulence Genes among Different Isolates. *J Microb Biochem Technol*. 2015; 7: 274-277.
 - 16 Sapana M.; Anu S.; KishorIngole and Sadiya S. Prevalence of *Pseudomonas aeruginosa* in Surgical Site Infection in a Tertiary Care Centre . *Int.J.Curr.Microbiol.App.Sci*. 2017. 6(4): 1202-1206
 - 17 Weinstein RA, Mayhall CG. The epidemiology of burn wound infections: then and now. *Clinical Infectious Diseases*. 2003;37(4):543-50.
 - 18 Alkateeb D.M.; Alwazni W.S.; Alghanimi Y.K.; Altuoma M.A.;Evaluation the immune status of the burn patients infected with bacteria *pseudomonas aeruginosa* in Karbala city. *IJRDP*. 2016; Vol. 5, No.4, pp 2219-2225.
 - 19 Alhamdy R.,A.,N. Antibacterial resistance of burn infections in Al-Hussain Teaching Hospital/Thi-Qar Province. 2015; V 10 N0.2, P: 68-82.
 - 20 Lari AR, Alaghehbandan R, Nikui R. Epidemiological study of 3341 burns patients during three years in Tehran, Iran. *Burns*. 2000; 26:49-53.
 - 21 Mabogunje OA, Khwaja MS, Lawrie JH. Childhood burns in Zaria, Nigeria. *Burns*. 1987;13:298-304.
 - 22 Othman N, Babakir-Mina M, Noori CK, Rashid PY. *Pseudomonas aeruginosa* infection in burn patients in Sulaimaniyah, Iraq: risk factors and antibiotic resistance rates. *J Infect Dev Ctries*. 2014; Nov 13; 8(11): 1498-502.
 - 23 Al-Zaidi, J.R. Antibiotic Susceptibility Patterns of *Pseudomonas aeruginosa* Isolated from Clinical and Hospital Environmental Samples in Nasiriyah, Iraq. *African Journal of Microbiology Research*, 2016.10, 844-849. <https://doi.org/10.5897/AJMR2016.8042>.
 - 24 Okon K, Agukwe P, Oladosu W, Balogun S, Uba A. Antibiotic resistance pattern of *Pseudomonas aeruginosa* isolated from clinical specimens in a tertiary hospital in northeastern Nigeria. *J. Microbiol*. 2009; 8(2):5-7
 - 25 Ekrem K, Rokan DK. Antibiotic susceptibility patterns of *Pseudomonas aeruginosa* strains isolated from various clinical specimens. *Sky J. Microbiol.Res*.2014; 2(2):13-17.
 - 26 Shewatatek G, Gizachew T, Molalegne B, Terefe G. Drug sensitivity of *Pseudomonas aeruginosa* from wound infections in Jimma university specialized hospital, Ethiopia. *J. Med. Med. Sci .Res*. 2014; 3(2):13-18.
 - 27 Morales-Espinosa R, Soberon-Chavez G, Delgado-Sapien G, Sandner-Miranda L. Genetic and phenotypic characterization of a *Pseudomonas aeruginosa* population with high frequency of genomic islands. *PLOS ONE* 2012; 7: e37459.
 - 28 Rhonda L. Feinbaum, Jonathan M. Urbach, Nicole T. Liberati, SlavicaDjonovic, Allison Adonizio, Anne-RuxandraCarvunis, Frederick M. Ausubel. Genome-Wide Identification of *Pseudomonas aeruginosa* Virulence-Related Genes Using a *Caenorhabditis elegans* Infection Model. Feinbaum RL, Urbach JM, Liberati NT, Djonovic S, Adonizio A, et al. (2012) Genome-Wide Identification of *Pseudomonas aeruginosa* Virulence-Related Genes Using a *Caenorhabditis elegans* Infection Model. *PLoSPathog*. 2012; 8(7).
 - 29 Lavenir R, Jocktane D, Laurent F, Nazaret S, Cournoyer B. Improved reliability of *Pseudomonas aeruginosa* PCR detection by the use of the *specifcecfx* gene target. *J Microbiol Methods* 2007; 70: 20-29.
 - 30 Lanotte, P.; Mereghetti, L.; Dartiguelongue, N.; Rastegar-Lari, A.; Gouden,A.and Quentin, R.: Genetic features of *Pseudomonas aeruginosa* isolatescystic fibrosis patients compared with those of isolates from other origins. *JMed Microbiol*. 2004; 53: 73-81.
 - 31 Khan, A.A. and Cerniglia, C.E. Detection of *Pseudomonas aeruginosa* from clinical and environmental samples by amplification of the exotoxin A geneusing PCR. *Appl. Environ. Microbiol*.1994; 60: 3739-3745.